Simcere Pharmaceutical Group's novel recombinant anti-VEGF antibody suvemcitug has shown a promising overall survival trend in still immature data in platinum-resistant ovarian cancer presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, which could position it well on this benchmark against other current mainstay same-class therapies.
Key Takeaways
-
Simcere is hopeful that its anti-VEGF antibody suvemcitug in combination with chemotherapy can beat chemotherapy alone for platinum-resistant ovarian cancer.
Back in January, the Nanjing-based drug maker announced the placebo-controlled Phase III SCORES trial with suvemcitug in combination with non-platinum...
Welcome to Scrip
Create an account to read this article
Already a subscriber?